榮暉控股(08213.HK)預計上半財年淨虧損約680萬港元-980萬港元
格隆匯11月4日丨榮暉控股(08213.HK)公佈,集團預期將於截至2021年9月30日止六個月錄得公司擁有人應占虧損介乎680萬港元至980萬港元,而去年同期則錄得公司擁有人應占溢利約520萬港元。
有關預期虧損乃主要由於以下各項的綜合影響所致:(i)其他收入減少,原因是於報吿期間內並無收取香港特別行政區政府推出之保就業計劃項下的工資補貼及香港特別行政區政府防疫抗疫基金的補貼並確認為其他收入,而去年同期則就集團於香港進行的業務活動於其他收入內錄得補貼總計約970萬港元;及(ii)經營開支增加,原因為本集團於2021年年初開始全面經營其新的醫療保健業務,並投入若干財務資源發展該新分部。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.